National

Serum Institute & Bharat Biotech Issue Joint Statement After A Spat

Both companies today communicated their combined intent to develop manufacture and supply the COVID-19 vaccines for India and abroad.

Pledging towards a smooth rollout of COVID-19 vaccines to India and the World, the Serum Institute of India and Bharat Biotech today released a joint statement. This comes shortly after the Serum institute CEO Adar Poonawalla called other vaccines ‘like water’, while Bharat Biotech CMD Krishna Ella alleged that participants were given paracetamol after being administered AstraZeneca vaccine to supress the side-effects.

However, both companies today communicated their combined intent to develop manufacture and supply the COVID-19 vaccines for India and abroad.

According to the statement, SII chief Adar Poonawala and Bharat Biotech CEO and MD Dr Krishna Ella, jointly on behalf of the two companies, said: “The more important task in front of them is saving the lives and livelihoods of populations in India and the world. Vaccines are a global public health good and they have the power to save lives and accelerate the return to economic normalcy at the earliest.”

“Now that two COVID-19 vaccines have been issued EUA (emergency use authorization) in India, the focus is on manufacturing, supply and distribution, such that populations that need it the most receive high quality, safe and efficacious vaccines. Both our companies are fully engaged in this activity and consider it our duty to the nation and the world at large to ensure a smooth rollout of vaccines. Each of our Companies continue their COVID-19 vaccines development activities as planned,” the statement further read.

Dear Readers,
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.

Related posts